The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC).
John Sarantopoulos
No relevant relationships to disclose
Noah M. Hahn
Consultant or Advisory Role - Celgene; Sanofi
Honoraria - Janssen Biotech; Sanofi
Research Funding - Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Merck; Millennium; Novartis; Sanofi
Celestia S. Higano
Honoraria - AbbVie; Amgen; Bayer; BHR Pharma; Dendreon; Endo/Orion; Ferring; Fresenius ; Genentech; Janssen; Medivation; Novartis; Pfizer
Research Funding - Algeta; Amgen; Aragon Pharmaceuticals; AstraZeneca; Bayer; Dendreon; Exelixis; Genentech; ImClone Systems; Medarex; Medivation; Millennium; Nerviano; Oncogenex; Sanofi ; Teva
E. Jane Leonard
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Bin Zhang
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Xiaofei Zhou
Employment or Leadership Position - Takeda
Claudio Dansky Ullmann
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Julie Nicole Graff
No relevant relationships to disclose